Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months
- 31 March 2000
- journal article
- clinical trial
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 22 (3), 315-325
- https://doi.org/10.1016/s0149-2918(00)80035-1
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Alternative Vaccination Schedules (0, 1, and 6 Months Versus 0, 1, and 12 Months) for a Recombinant OspA Lyme Disease VaccineClinical Infectious Diseases, 1999
- Vaccination against Lyme Disease with RecombinantBorrelia burgdorferiOuter-Surface Lipoprotein A with AdjuvantNew England Journal of Medicine, 1998
- Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adultsVaccine, 1996
- The Public Health Impact of Lyme Disease in MarylandThe Journal of Infectious Diseases, 1996
- Underreporting of Lyme Disease by Connecticut Physicians, 1992Journal of Public Health Management & Practice, 1996
- Statistical considerations in the quantitation of serum immunoglobulin levels using the Enzyme-Linked Immunosorbent Assay (ELISA)Journal of Immunological Methods, 1987